Dose response in prostate cancer with 8-12 years' follow-up

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 2, 2002, Pages 427-435

  Hanks, Gerald E ^a   Hanlon, Alexandra L ^a   Epstein, Barry ^a   Horwitz, Eric M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Dose response relationship; Prostate specific antigen; Prostatic neoplasms; Three dimensional conformal radiotherapy

Indexed keywords

BIOCHEMISTRY; DOSIMETRY; RADIOTHERAPY; STATISTICAL METHODS; TUMORS;

TUMOR STAGES;

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; ONCOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; STATISTICAL SIGNIFICANCE; UROGENITAL TRACT DISEASE;

ACTUARIAL ANALYSIS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RECTUM; TREATMENT OUTCOME;

EID: 0036805444     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02954-1     Document Type: Article

References (29)

1. Hanks G.E., Lee W.R., Hanlon A.L., et al. Conformal technique dose escalation in prostate cancer Improved cancer control with higher doses in patients with pre-treatment PSA ≥10 ng/ml . (abstr) Int J Radiat Oncol Biol Phys. 32:1995;141.
2. Hanks G.E., Lee W.R., Hanlon A.L., et al. Conformal technique for dose escalation for prostate cancer Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen >10 ng/ml . Int J Radiat Oncol Biol Phys. 35:1996;861-868.
3. Hanks G.E., Hanlon A.L., Pinover W.H., et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys. 46:2000;823-832.
4. Pinover W.H., Hanlon A.L., Horwitz E.M., et al. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/ml prostate cancer. Int J Radiat Oncol Biol Phys. 47:2000;649-654.
5. Pollack A., Zagars G., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 18:2000;3904-3911.
6. Fiveash J.B., Hanks G.E., Roach M. III, et al. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer. A multi-institutional review. Int J Radiat Oncol Biol Phys. 47:2000;335-342.
7. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 166:2001;876-881.
8. Kupelian P.A., Buchsbaum J.C., Reddy C.A., et al. Radiation dose response in patients with favorable localized prostate cancer (stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10). Int J Radiat Oncol Biol Phys. 50:2001;621-625.
9. Fukunaga-Johnson N., Sandler H.M., McLaughlin P.W., et al. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 38:1997;311-317.
10. Roach M. III, Meehan S., Kroll S., et al. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol. 156:1996;1719-1723.
11. Hanks G.E., Hanlon A.L., Pinover W.H., et al. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am. 5:1999;152-158.
12. American Joint Committee on Cancer . Prostate. Beahrs O.H., Henson D.E., Hutter R.V.P., et al. Manual for the staging of cancer. 1992;181-186 JB Lippincott, Philadelphia.
13. American Joint Committee on Cancer . Prostate. Fleming I.D., Cooper J.S., Henson D.E., AJCC cancer staging manual. 1997;219-224 JB Lippincott, Philadelphia.
14. International Commission on Radiation Units and Measurements . ICRU Report 50 Prescribing, recording, and reporting photon beam therapy . 1993;3-16 International Commission on Radiation Units and Measurements, Bethesda.
15. American Society for Therapeutic Radiology and Oncology Consensus Panel . Consensus statement Guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
16. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
17. Wilcoxon F. Individual comparison by ranking methods. Biometrics. 1:1945;80-83.
18. Cox D.R. Regression models and life tables. J R Stat Soc. 34:1972;187-220.
19. Coia L.R., Myerson R.J., Tepper J.E. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys. 31:1995;1213-1236.
20. Lee W.R., Hanks G.E., Hanlon A.L., et al. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer Further evidence for a significant dose effect . Int J Radiat Oncol Biol Phys. 35:1996;251-257.
21. Bolla M. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol. 35:1999;23-26.
22. Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 49:2001;937-946.
23. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 50:2001;1243-1252.
24. Horwitz E.M., Hanlon A.L., Pinover W.H., et al. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 92:2001;1281-1287.
25. Bey P., Carrie C., Beckendorf V., et al. Dose escalation with 3D-CRT in prostate cancer French study of dose escalation with conformal 3D radiotherapy in prostate cancer - Preliminary results . Int J Radiat Oncol Biol Phys. 48:2000;513-517.
26. Michalski J.M., Purdy J.A., Winter K., et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 94-06. Int J Radiat Oncol Biol Phys. 46:2000;391-402.
27. Ryu J.K., Winter K., Michalski J.M., et al. Preliminary report of toxicity following 3D conformal radiation therapy (3DCRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 51:2001;136-137.
28. Lattanzi J.P., McNeeley S., Pinover W.H., et al. A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer. Int J Radiat Oncol Biol Phys. 43:1999;719-725.
29. Mah D, Steckner M, Palacia E, Mitra R, Richardson T, Hanks GE. Characteristics and quality assurance of a dedicated open 0.23 T MRI for radiation therapy simulation. Med Phys 2002. In press.